Diacylglycerol kinases in cancer
详细信息 查看全文
- 作者：Isabel Mé ; rida ; imerida@cnb.csic.es ; Pedro Torres-Ayuso ; Antonia Á ; vila-Flores ; Javier Arranz-Nicolá ; s ; Elena Andrada ; Marí ; a Tello-Lafoz ; Rosa Lié ; bana ; Raquel Arcos
- 刊名：Advances in Biological Regulation
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：63
- 期：Complete
- 页码：22-31
- 全文大小：1065 K
- 卷排序：63
文摘
Diacylglycerol kinases (DGK) are a family of enzymes that catalyze the transformation of diacylglycerol into phosphatidic acid. In T lymphocytes, DGKα and ζ limit the activation of the PLCγ/Ras/ERK axis, providing a critical checkpoint to inhibit T cell responses. Upregulation of these isoforms limits Ras activation, leading to hypo-responsive, anergic states similar to those caused by tumors. Recent studies have identified DGKα upregulation in tumor lymphocyte infiltrates, and cells from DGKα and ζ deficient mice show enhanced antitumor activity, suggesting that limitation of DAG based signals by DGK is used by tumors to evade immune attack.DGKα expression is low or even absent in other healthy cells like melanocytes, hepatocytes or neurons. Expression of this isoform, nevertheless is upregulated in melanoma, hepatocarcinoma and glioblastoma where DGKα contributes to the acquisition of tumor metastatic traits. A model thus emerges where tumor milieu fosters DGKα expression in tumors as well as in tumor infiltrating lymphocytes with opposite consequences.Here we review the mechanisms and targets that facilitate tumor “addiction” to DGKα, and discuss its relevance in the more advanced forms of cancer for tumor immune evasion. A better knowledge of this function offers a new perspective in the search of novel approaches to prevent inhibition of immune attack in cancer.Part of the failure in clinical progress may be attributed to the complexity of the tumor/T lymphocyte interaction. As they develop, tumors use a number of mechanisms to drive endogenous, tumor reactive T cells to a general state of hyporesponsiveness or anergy. A better knowledge of the molecular mechanisms that tumors use to trigger T cell anergic states will greatly help in the advance of immunotherapy research.